Trump Reg Freeze Could Put Controversial FDA Draft Guidances On Hold

January 24, 2017 at 6:16 PM
President Donald Trump put heads of executive departments and agencies on notice that no new rules or guidances should be sent to the Office of the Federal Register (OFR) until a Trump-appointed or designated agency head reviews and approves them, potentially putting controversial FDA draft guidances and notices on such hot-button issues as off-label use, new dietary ingredients, compounding and biosimilars on hold. The order allows for new regulations under certain health, safety, financial, or national security matters in emergency...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.